Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Trepel Website

Jane B. Trepel

Selected Publications

1)  Walton-Diaz A, Khan S, Bourboulia D, Trepel JB, Neckers L, Mollapour M.
Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity.
Future Med Chem. 5: 1059-71, 2013.
[Journal]
2)  Yoshida S, Tsutsumi S, Muhlebach G, Sourbier C, Lee MJ, Lee S, Vartholomaiou E, Tatokoro M, Beebe K, Miyajima N, Mohney RP, Chen Y, Hasumi H, Xu W, Fukushima H, Nakamura K, Koga F, Kihara K, Trepel J, Picard D, Neckers L.
Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis.
Proc. Natl. Acad. Sci. U.S.A. 110: E1604-12, 2013.
[Journal]
3)  Beebe K, Mollapour M, Scroggins B, Prodromou C, Xu W, Tokita M, Taldone T, Pullen L, Zierer BK, Lee MJ, Trepel J, Buchner J, Bolon D, Chiosis G, Neckers L.
Posttranslational modification and conformational state of Heat Shock Protein 90 differentially affect binding of chemically diverse small molecule inhibitors.
Oncotarget. 4: 1065-74, 2013.
[Journal]
4)  Korde N, Carlsten M, Lee MJ, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tageja N, Roschewski M, Zingone A, Costello R, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Trepel J, Childs R, Landgren O.
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
Haematologica. 99: e81-3, 2014.
[Journal]
5)  Mollapour M, Bourboulia D, Beebe K, Woodford MR, Polier S, Hoang A, Chelluri R, Li Y, Guo A, Lee MJ, Fotooh-Abadi E, Khan S, Prince T, Miyajima N, Yoshida S, Tsutsumi S, Xu W, Panaretou B, Stetler-Stevenson WG, Bratslavsky G, Trepel JB, Prodromou C, Neckers L.
Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors.
Mol. Cell. 53: 317-29, 2014.
[Journal]
6)  Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, Szabo E, Lee MJ, Trepel JB, Browne SK, Rosen LB, Yu Y, Steinberg SM, Chen HX, Riely GJ, Giaccone G.
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
Lancet Oncol. 15: 191-200, 2014.
[Journal]
7)  Giubellino A, Shankavaram U, Bullova P, Schovanek J, Zhang Y, Shen M, Patel N, Elkahloun A, Lee MJ, Trepel J, Ferrer M, Pacak K.
High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma.
PLoS ONE. 9: e90458, 2014.
[Journal]
8)  Nguyen P, Lee S, Lorang-Leins D, Trepel J, Smart DK.
SIRT2 Interacts with Beta-catenin to Inhibit Wnt Signaling Output in Response to Radiation-Induced Stress.
Mol. Cancer Res. 2014.
[Journal]
9)  Neckers L, Trepel JB.
Stressing the development of small molecules targeting HSP90.
Clin. Cancer Res. 20: 275-7, 2014.
[Journal]
10)  Park SR, Speranza G, Piekarz R, Wright JJ, Kinders RJ, Wang L, Pfister T, Trepel JB, Lee MJ, Alarcon S, Steinberg SM, Collins J, Doroshow JH, Kummar S.
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas.
Cancer Chemother. Pharmacol. 71: 981-90, 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 8/1/2014.